A recent trial showed its new 2-for-1 injection was more effective on both illnesses than existing individual shots.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The regulator sees some patents as ploys to keep companies from developing cheaper generic versions of 20 different brand-name drugs.
Blue Origin is going slower than SpaceX, but it also nailed a massive rocket launch on the first try. Jeff Bezos is back in the space race.
The listing marks a potentially triumphant comeback story and an insult of sorts to the embattled London stock exchange.
With the way things are going today, it’s becoming increasingly hard to figure out what’s going on with the oil market.